Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease
Attia, Ahmed H, Gadelkarim M, Morsi M, Morsi M, Awad K, Elnenny M, Ghanem E, El-Jaafary S, Negida A
CNS & neurological disorders drug targets · 10 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2016-12-02 · CNS Neurol Disord Drug Targets · vol. 16 · número 2 · págs. 169–175
- Editorial
- Bentham Science Publishers
- Citado
- 19 citas · más que el 55% de estudios similares · 0.7× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Parkinson's Disease Mechanisms and Treatments · Muscle metabolism and nutrition · Nutrition and Health in Aging
- Palabras clave
- Neuroprotection, Parkinson's disease, Creatine, Meta-analysis, Medicine, Stroke (engine), Disease, Randomized controlled trial, Clinical trial, Internal medicine
- MeSH
- animals, humans, parkinson disease, creatine, antiparkinson agents, neuroprotective agents, randomized controlled trials as topic
9 autores
- Attia Attia🇪🇬Scientific Research Group in Egypt
- Hussien Ahmed🇪🇬Scientific Research Group in Egypt
- Mohamed Gadelkarim🇪🇬Scientific Research Group in Egypt
- Mahmoud Morsi🇪🇬Scientific Research Group in Egypt
- Kamal Awad🇪🇬Scientific Research Group in Egypt
- Mohamed Elnenny🇪🇬Scientific Research Group in Egypt
- Esraa Ghanem🇪🇬Scientific Research Group in Egypt
- Shaimaa Ibrahim El-Jaafary🇪🇬Scientific Research Group in Egypt
- Ahmed Negida🇪🇬Zagazig University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Creatine is an antioxidant agent that showed neuroprotective effects in animal models of Parkinson's disease (PD). Creatine was selected by the National Institute of Neurological Disorders and Stroke as a possible disease modifying agent for Parkinson's disease. Therefore, many clinical trials evaluated the efficacy of creatine for patients with PD. The aim of this systematic review and meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the efficacy of Creatine for patients with PD.
Methods
We followed PRISMA statement guidelines during the preparation of this systematic review and meta-analysis. A computer literature search for PubMed, EBSCO, web of science and Ovid Midline was carried out. We included RCTs comparing creatine with placebo in terms of motor functions and quality of life. Outcomes of total Unified Parkinson's Disease Rating Scale (UPDRS), UPDRS I, UPDRS II, and UPDRS III were pooled as mean difference (MD) between two groups from baseline to the endpoint. Statistical heterogeneity was assessed by visual inspection of the forest plot and measured by chi-square and I square tests.
Results
Three RCTs (n=1935) were included in this study. The overall effect did not favor either of the two groups in terms of: UPDRS total score (MD 1.07, 95% CI [3.38 to 1.25], UPDRS III (MD 0.62, 95% CI [2.27 to 1.02]), UPDRS II (MD 0.03, 95% CI [0.81 to 0.86], or UPDRS I (MD 0.03, 95% CI [0.33 to 0.28]).
Conclusion
Current evidence does not support the use of creatine for neuroprotection against PD. Future well-designed, randomized controlled trials are needed.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.